Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT06644183 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Relapsed Leukemia
Chronic Lymphocytic Leukemia
Relapsed Cancer
Refractory Leukemia

Interventions

DRUG: Roginolisib
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Jennifer R. Brown, MD, PhD

Collaborators

[object Object]